My current and future work focuses on answering the question: Can small molecules be used to 'dial in' specific transcriptional profiles that will reprogram cell states by targeting transcription factors? To do this, I will implement the critical path for prioritization strategy (Research), from which I will discover chemical probes that will reprogram the dysregulated cell types within the tumor-immune microenvironment to ascertain their immunosuppressive contribution to immune checkpoint blockade therapy resistance.
 
Surveying key transcription factors that are the dominant drivers of these dysfunctional cell states will assist in deconvoluting the complexity of the tumor-immune microenvironment and clarify their therapeutic relevance as tractable targets for immunotherapy.

 

                                                  The Tumor-immune Microenvironment